$3.955
-0.274 (-6.94%)Zum Schluss
ANTX-News
ANTX-Events
AN2 Therapeutics Receives FDA Clearance for New Drug Application
AN2 Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for epetraborole in polycythemia vera. The Company has now received regulatory clearance in all planned jurisdictions for the global study and expects to initiate the trial in the fourth quarter of 2026.
AN2 Therapeutics Receives Funding Extension from Gates Foundation
AN2 Therapeutics (ANTX) announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis research collaboration with GSK (GSK) focused on the development of boron-based leucyl-tRNA synthetase inhibitors.
AN2 Therapeutics to Present Epetraborole Data at SOHO 2026 Annual Meeting
The company states: "AN2 Therapeutics announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas." "These abstracts provide insights into the potential beneficial hematological effects of epetraborole across both clinical and nonclinical studies and strengthen our understanding of the exposure-response relationships that we believe support its development in polycythemia vera," said George H. Talbot, M.D. Co-Founder and Senior Medical Advisor of AN2 Therapeutics.
AN2 Therapeutics Appoints Cameron Trenor as Chief Medical Officer
AN2 Therapeutics announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Most recently, Dr. Trenor served as Chief Medical Officer of Cellarity
AN2 Therapeutics to Launch Three Phase 2 Clinical Trials
"AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs. Our near-term focus is advancing start-up activities for the Phase 2 EBO-PV-201 study in polycythemia vera. We recently held a pre-IND meeting with the FDA and are expanding the Phase 2 study to include sites in the U.S. and Australia," said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. "Enrollment is ongoing in an investigator-initiated Phase 2 study in M. abscessus lung disease. In our chronic Chagas program, compelling non-human primate efficacy data and a favorable clinical PK and safety profile from our Phase 1 study support planned initiation of a Phase 2 trial by year-end. We are also expanding our pipeline, having declared our first development candidate for solid tumors earlier this year and expecting to advance a second development candidate by the end of 2026. Collectively, these achievements underscore the potential of our boron chemistry platform to deliver differentiated therapies across multiple disease areas."
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.